KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2023 - 2025)

Biocryst Pharmaceuticals' Other Non-Current Assets history spans 8 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 9.99% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.7 million, up 9.99%, while the annual FY2025 figure was $5.7 million, 9.99% up from the prior year.
  • Other Non-Current Assets reached $5.7 million in Q4 2025 per BCRX's latest filing, up from $4.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.0 million in Q1 2024 to a low of $80000.0 in Q4 2023.
  • Average Other Non-Current Assets over 3 years is $6.4 million, with a median of $5.4 million recorded in 2024.
  • The largest YoY upside for Other Non-Current Assets was 6346.25% in 2024 against a maximum downside of 80.6% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $80000.0 in 2023, then surged by 6346.25% to $5.2 million in 2024, then rose by 9.99% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Other Non-Current Assets are $5.7 million (Q4 2025), $4.4 million (Q3 2025), and $3.6 million (Q2 2025).